PHIO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Phio Pharmaceuticals's net margin of -49.65%. Phio Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Phio Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 196.3%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.08%. Given that Phio Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Phio Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Phio Pharmaceuticals has a beta of 1.278, which suggesting that the stock is 27.797% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Phio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Phio Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Phio Pharmaceuticals's net income of -$1.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Phio Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Phio Pharmaceuticals's net margin of -2357.27%. Phio Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Phio Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 196.3%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 772.06%. Given that Palatin Technologies has higher upside potential than Phio Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Phio Pharmaceuticals.

Phio Pharmaceuticals has a beta of 1.278, which suggesting that the stock is 27.797% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Phio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Phio Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Phio Pharmaceuticals's net income of -$1.5M is higher than Palatin Technologies's net income of -$2.4M. Notably, Phio Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Phio Pharmaceuticals's net margin of --. Phio Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Phio Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 196.3%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 412.82%. Given that Theriva Biologics has higher upside potential than Phio Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Phio Pharmaceuticals.

Phio Pharmaceuticals has a beta of 1.278, which suggesting that the stock is 27.797% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Phio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Phio Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Phio Pharmaceuticals's net income of -$1.5M is higher than Theriva Biologics's net income of -$4.4M. Notably, Phio Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Traws Pharma has a net margin of -- compared to Phio Pharmaceuticals's net margin of -14868.42%. Phio Pharmaceuticals's return on equity of -- beat Traws Pharma's return on equity of -124.39%.

Phio Pharmaceuticals has a consensus price target of $4.00, signalling upside risk potential of 196.3%. On the other hand Traws Pharma has an analysts' consensus of -- which suggests that it could grow by 116.61%. Given that Phio Pharmaceuticals has higher upside potential than Traws Pharma, analysts believe Phio Pharmaceuticals is more attractive than Traws Pharma.

Phio Pharmaceuticals has a beta of 1.278, which suggesting that the stock is 27.797% more volatile than S&P 500. In comparison Traws Pharma has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.177%.

Phio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Traws Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals pays -- of its earnings as a dividend. Traws Pharma pays out -- of its earnings as a dividend.

Phio Pharmaceuticals quarterly revenues are --, which are smaller than Traws Pharma quarterly revenues of $57K. Phio Pharmaceuticals's net income of -$1.5M is higher than Traws Pharma's net income of -$8.5M. Notably, Phio Pharmaceuticals's price-to-earnings ratio is -- while Traws Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals is -- versus 11.20x for Traws Pharma. Usually stocks with elevated PS ratios are considered overvalued.